Difference between revisions of "Crizanlizumab (Adakveo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
m (→Also known as) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *2019-11-15: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with [[Sickle cell anemia|sickle cell disease]]. ''(Based on SUSTAIN)'' |
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2020-10-28: Initial conditional authorization for preventing painful crises in patients with [[Sickle cell anemia|sickle cell disease]] aged 16 years and older. ''(Based on SUSTAIN)'' | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' SEG-101 |
*'''Generic name:''' crizanlizumab-tmca | *'''Generic name:''' crizanlizumab-tmca | ||
*'''Brand name:''' Adakveo | *'''Brand name:''' Adakveo | ||
| Line 20: | Line 23: | ||
[[Category:Sickle cell anemia medications]] | [[Category:Sickle cell anemia medications]] | ||
| + | [[Category:EMA approved in 2020]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Latest revision as of 13:12, 8 September 2023
Mechanism of action
Definition from the NCI Drug Dictionary: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells.
Diseases for which it is used
History of changes in FDA indication
- 2019-11-15: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. (Based on SUSTAIN)
History of changes in EMA indication
- 2020-10-28: Initial conditional authorization for preventing painful crises in patients with sickle cell disease aged 16 years and older. (Based on SUSTAIN)
Also known as
- Code name: SEG-101
- Generic name: crizanlizumab-tmca
- Brand name: Adakveo